🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06850116
Active, not recruiting Observational

Analysis of Immediate Urinary Continence Predictors After RS-RARP

NCT06850116 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Observational
Started
2025-01-01
Last updated
2025-04-04

Condition(s) studied

Prostate Cancer (Post Prostatectomy)Urinary ContinenceRetzius-sparing Robot-assisted Radical Prostatectomy

Investigational drug(s) / intervention(s)

Retzius-sparing robot-assisted radical prostatectomy

Retzius-sparing robot-assisted radical prostatectomy: Retzius-sparing robot-assisted radical prostatectomy

Study summary

This study is a retrospective, single-center clinical trial. It aims to retrospectively analyze the immediate postoperative urinary continence recovery in prostate cancer patients who underwent Retzius-sparing robot-assisted radical prostatectomy in the investigators' center. Based on the general conditions of patients, relevant perioperative clinical indicators, and parameters related to the sphincter and prostate gland measured by MRI, it explores the influencing factors of immediate urinary continence recovery after Retzius-sparing robot-assisted radical prostatectomy in prostate cancer patients and constructs a relevant prediction model, thereby providing clinical guidance value for predicting immediate postoperative urinary continence recovery.

Eligibility

Sex
MALE
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * Prostate cancer diagnosed by prostate biopsy and underwent Retzius-sparing robot-assisted radical prostatectomy in the investigators' hospital. * Received plain and contrast-enhanced pelvic or prostate MRI examinations before surgery. * Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 1. * Complete clinicopathological data. * In good general condition, without infections, autoimmune diseases, hematological diseases or other malignant tumors. * Complete postoperative follow-up data, with a postoperative follow-up time of no less than 6 months. Exclusion Criteria: * The patient has surgical contraindications. * The patient has contraindications for MRI examination. * Preoperative presence of congenital urinary system malformations, urinary incontinence or severe lower urinary tract symptoms, and with a history of urinary catheter or previous transurethral resection of the prostate (TURP) surgery. * Having received neoadjuvant treatments that may affect the results of this study, such as radiotherapy or hormonal therapy. * The patient has other concurrent malignant tumors. * The patient has delayed extubation (\> 14 days). * The patient's clinical, imaging and pathological data are incomplete or the patient is lost to follow-up.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
first hospital affiliated of Fujian medical university Fuzhou Fujian

More First Affiliated Hospital of Fujian Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06850116 on ClinicalTrials.gov ↗ ← All trials in China